Personalis, Inc. is making strides in the cancer genomics industry, providing sequencing and data analysis services globally to support the development of cancer therapies and large-scale genetic research programs. The company's innovative NeXT Platform allows for data analysis of a tumor and its immune microenvironment, all from a single limited tissue or plasma sample. Personalis also offers ImmunoID Next for tumor profiling from tissue, NeXT Liquid Biopsy for tumor profiling from plasma, NeXT Personal for personalized tumor tracking for patients, NeXT Dx Test for genomic cancer profiling, and NeXT SHERPA and NeXT NEOPS, both for neoantigen prediction capabilities. In addition to its NeXT Platform, the company provides the ACE platform for clinical and therapeutic applications, allowing for neoantigen prediction, biomarker identification, and novel drug target selection. Personalis' customer base includes pharmaceutical, biopharmaceutical, diagnostic testing, and biotechnology companies, healthcare providers, universities, non-profits, and government entities. Personalis, Inc. was founded in 2011 and is headquartered in Fremont, California. As personalized medicine gains traction in the healthcare industry, Personalis' unique approach to cancer genomics may prove to be a valuable asset in the development of new cancer therapies and treatments.
Personalis's ticker is PSNL
The company's shares trade on the NASDAQ stock exchange
They are based in Menlo Park, California
There are 51-200 employees working at Personalis
It is personalis.com
Personalis is in the Healthcare sector
Personalis is in the Biotechnology industry
The following five companies are Personalis's industry peers: